The Diabetes business unit at Abbott (NYSE:ABT) has gotten off to a hot start in 2024, with some significant developments on the CGM front. With the recent FDA clearance of two over-the-counter sensors following significant automated insulin pump integrations, 2024 has been full of good news for the company. Speaking to Drug Delivery Business News at […]